JP Morgan Chase
RAPT

JP Morgan Chase’s RAPT Therapeutics RAPT Stock Holding History

JP Morgan Chase’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,125
Closed -$76.3K – 7628
2024
Q2 		$76.3K Buy
+3,125
New +$144K ﹤0.01% 5669

JP Morgan Chase's RAPT Position: Q1 2026 in Review

JP Morgan Chase sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 1,668 shares — an estimated $56.5K sold.

JP Morgan Chase first reported a position in RAPT in Q4 2019 and held it in 25 quarters. The position peaked at $830K in Q2 2020. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

  • JP Morgan Chase reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
  • JP Morgan Chase sold 1,668 RAPT Therapeutics shares in Q1 2026, an estimated $56.5K.
  • JP Morgan Chase first reported a position in RAPT Therapeutics in Q4 2019 and held it in 25 quarters.
  • JP Morgan Chase's RAPT Therapeutics position peaked at $830K in Q2 2020.
  • 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.